KRAS and colorectal carcinoma: Since RTK signaling in CRC is dominated by wild-type EGFR, a KRAS (G12C) inhibitor combined with an anti-EGFR monoclonal antibody can block receptor signaling rather than inhibit EGFR kinase activity [102–104].